PMID: 1505562DOI: 10.1093/oxfordjournals.eurheartj.a060324Aug 1, 1992Paper

Electrophysiological and haemodynamic effects of lidocaine and ajmaline in the management of sustained ventricular tachycardia

European Heart Journal
M ManzB Lüderitz

Abstract

The electrophysiological and haemodynamic effects of lidocaine (100 mg) and ajmaline (50 mg) were evaluated while attempting to interrupt sustained ventricular tachycardia. The study was performed as a prospective, non-blinded, randomized investigation in 61 patients. Lidocaine terminated ventricular tachycardia in four of 31 patients, ajmaline in 19 of 30 patients (P less than 0.001). QRS and RR intervals during ventricular tachycardia were prolonged by ajmaline from 164 +/- 28 ms to 214 +/- 49 ms and from 371 +/- 86 ms to 479 +/- 137 ms (P less than 0.001), respectively; lidocaine did not influence these parameters. The duration of the return cycles after termination of ventricular tachycardia did not differ between the two groups. Lidocaine did not change cardiac output during ventricular tachycardia whereas cardiac output increased significantly under ajmaline from 3.5 +/- 1.21.min-1 to 5.5 +/- 1.91.min-1 (P less than 0.001). It is concluded that anti-arrhythmic agents such as ajmaline, which slow conduction velocity and prolong refractoriness, are more effective than lidocaine in the medical treatment of haemodynamically stable, sustained ventricular tachycardia.

Citations

ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias)

Oct 15, 2003·Circulation·Carina Blomström-LundqvistUNKNOWN European Society of Cardiology Committee for Practice Guidelines. Writing Committee to Develop Guidelines for the Management

Class Ia anti-arrhythmic drug ajmaline blocks HERG potassium channels: mode of action

Dec 16, 2004·Naunyn-Schmiedeberg's Archives of Pharmacology·Claudia KieseckerJohann Kiehn

The diagnosis and management of ventricular arrhythmias

Feb 24, 2011·Nature Reviews. Cardiology·Kurt C Roberts-ThomsonPrashanthan Sanders

Inhibition of cardiac Kv1.5 and Kv4.3 potassium channels by the class Ia anti-arrhythmic ajmaline: mode of action

Jul 9, 2013·Naunyn-Schmiedeberg's Archives of Pharmacology·F FischerE P Scholz

Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force

Aug 31, 2014·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Bulent GorenekIrene Savelieva

Effect of magnesium on sustained ventricular tachycardia

Jun 1, 1997·Herz·M ManzB Lüderitz

NA+- and K+-channels as molecular targets of the alkaloid ajmaline in skeletal muscle fibres

Mar 14, 2007·British Journal of Pharmacology·O FriedrichR H A Fink

[Amiodaron for treatment of perioperative cardiac arrythmia: a broad spectrum antiarrythmetic agent?].

Aug 16, 2008·Der Anaesthesist·N ButteP Teschendorf

[In Process Citation].

Feb 4, 2010·Medizinische Klinik·Marcus L Koller, Burghard Schumacher

Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force

Aug 30, 2014·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Bulent GorenekUwe Zeymer

Transvenous atrial cardioversion threshold in patients with implantable cardioverter defibrillator: influence of active pectoral can

Feb 17, 1999·Pacing and Clinical Electrophysiology : PACE·A HeiselH Schieffer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Related Papers

ContactHelpTerms Privacy Cookies
© 2022 Meta ULC. All rights reserved